September 21 (WNN) — Johnson & Johnson announced Tuesday that its one-shot COVID-19 vaccine has performed well in real-world studies, providing long-lasting protection against the virus and as a booster for months after the original dose. Enhances the immune system when administered in.
The pharma company announced the release of late-stage clinical data for an adenovirus-based vaccine, manufactured by Janssen, a subsidiary of Johnson & Johnson, which was granted emergency use authorization in the United States earlier this year.
Johnson & Johnson said it conducted two studies in which volunteers received a second vaccine dose between two and six months after the first. It said the booster increased the immune response in recipients between the ages of 18 and 55.
When given two months after the first dose, the company said the booster shot was 100% effective in protecting recipients from severe COVID-19 and 75% effective in preventing symptomatic COVID-19 worldwide. The data said it was 94% effective in preventing symptomatic COVID-19 in the United States.
“When a booster for the Johnson & Johnson COVID-19 vaccine was given two months after the first shot, antibody levels were four to six times higher after a single shot,” the company said in a statement.
In another study, which tested a booster dose after six months, Johnson & Johnson noted that antibodies increased nine to 12-fold in recipients.
The company also noted that a single dose of the vaccine was 79 percent effective against infection and 81 percent effective in preventing hospitalizations in the United States between the end of March and July.
“There was no evidence of reduced effectiveness over the study period in which the delta version became effective in the US,” it noted.
“Our single-shot vaccine generates a strong immune response and long-lasting immune memory. And, when given a booster of the Johnson & Johnson COVID-19 vaccine, the protection against COVID-19 is further enhanced Dr. Mathai Maimon, Global Head of Research and Development, Janssen, said in a statement.
The clinical data released Tuesday has not yet been peer-reviewed.
Johnson & Johnson said it is in talks with US and European regulators about a possible booster dose. Last week, the Food and Drug Administration recommended a booster for the Pfizer vaccine in at-risk Americans 65 and over.